Engineered Hydroxyapatite–Baicalin Nanorods with Sharp Edges for Broad-Spectrum Antiviral Applications
Source abstract
Abstract
The sharp-edged structure of inorganic nanomaterials has attracted considerable interest due to its potential to confer broad-spectrum antiviral properties. Herein, a series of hydroxyapatite-balance-based (HA-B) nanorods with well-defined aspect ratios were synthesized to investigate their antiviral activity. Among them, HA-B 0.05wt% exhibited the highest aspect ratio (AR = 11.7 ± 4.7) and demonstrated potent, broad-spectrum antiviral activity against enveloped virus, including pseudorabies virus (PRV, DNA virus), transmissible gastroenteritis virus (TGEV, RNA virus), and porcine epidemic diarrhea virus (PEDV, RNA virus). For extracellular viruses, HA-B 0.05wt% exerts its antiviral effect primarily through the physical disruption of viral envelopes, facilitated by its sharp-edged nanostructures. In the case of intracellular viruses, HA-B 0.05wt% mitigates infection by attenuating virus-induced intracellular reactive oxygen species (ROS) accumulation and activating the host’s innate immune responses, thereby effectively suppressing viral replication and release. Furthermore, in vivo evaluation demonstrated that treatment with HA-B 0.05wt% significantly reduced viral load and improved survival rates in PRV-infected mice. Collectively, these findings highlight HA-B 0.05wt% as a promising candidate for broad-spectrum antiviral therapy with potential applications in biosecurity and infectious disease control.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Bone Tissue Engineering Materials · Viral gastroenteritis research and epidemiology · Animal Virus Infections Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Center for Infectious Diseases Control (CIDC)
Sichuan Agricultural University
Key Laboratory of Animal Disease and Human Health of Sichuan Province
Translational Medicine Laboratory
The First Affiliated Hospital of Wenzhou Medical University
State Key Laboratory of Medicinal Chemical Biology
Nankai University
Funding
Sichuan Agricultural University · Science and Technology Department of Sichuan Province · National Natural Science Foundation of China
References (61)
Show source-provided references
1. 10.1002/smll.20190620610.1002/smll.201906206 ↗
2. 10.1038/nmat505310.1038/nmat5053 ↗
3. 10.1021/acsnano.0c0411710.1021/acsnano.0c04117 ↗
4. 10.1002/smll.20190264110.1002/smll.201902641 ↗
5. 10.1021/acsami.5b0687610.1021/acsami.5b06876 ↗
6. 10.1002/adhm.20230418610.1002/adhm.202304186 ↗
7. 10.1002/adfm.20240202310.1002/adfm.202402023 ↗
8. 10.1002/jmv.7010110.1002/jmv.70101 ↗
9. 10.1002/sstr.20220002110.1002/sstr.202200021 ↗
10. 10.1016/j.msec.2019.11010010.1016/j.msec.2019.110100 ↗
11. 10.1016/j.jviromet.2019.11368810.1016/j.jviromet.2019.113688 ↗
12. 10.1038/srep3585110.1038/srep35851 ↗
13. 10.1590/1519-6984.27956410.1590/1519-6984.279564 ↗
14. 10.1098/rsos.24217910.1098/rsos.242179 ↗
15. 10.1002/adma.20240336210.1002/adma.202403362 ↗
16. 10.1080/17425247.2024.236465210.1080/17425247.2024.2364652 ↗
17. 10.1007/s12598-021-01776-310.1007/s12598-021-01776-3 ↗
18. 10.1039/D0BM01320J10.1039/D0BM01320J ↗
19. 10.1021/acs.cgd.5b0011310.1021/acs.cgd.5b00113 ↗
20. 10.1002/adma.20210089510.1002/adma.202100895 ↗
21. 10.1021/acsami.1c1780410.1021/acsami.1c17804 ↗
22. 10.1002/adma.20060003310.1002/adma.200600033 ↗
23. 10.1039/b400317a10.1039/b400317a ↗
24. 10.1021/acsnano.1c0828110.1021/acsnano.1c08281 ↗
25. 10.1007/s13659-020-00257-x10.1007/s13659-020-00257-x ↗
26. 10.1101/2020.04.13.03868710.1101/2020.04.13.038687 ↗
27. 10.1093/jac/dkt53410.1093/jac/dkt534 ↗
28. 10.3390/v708284110.3390/v7082841 ↗
29. 10.1038/s41598-021-98949-y10.1038/s41598-021-98949-y ↗
30. 10.1016/j.apsb.2014.03.00210.1016/j.apsb.2014.03.002 ↗
31. 10.1038/s41467-018-02932-710.1038/s41467-018-02932-7 ↗
32. 10.1021/acs.langmuir.8b0015110.1021/acs.langmuir.8b00151 ↗
33. 10.1038/s41598-019-55428-910.1038/s41598-019-55428-9 ↗
34. 10.2147/IJN.S23292610.2147/IJN.S232926 ↗
35. 10.1016/j.compositesb.2021.10894410.1016/j.compositesb.2021.108944 ↗
36. 10.1039/D0RA09673C10.1039/D0RA09673C ↗
37. 10.1016/j.tiv.2009.01.00710.1016/j.tiv.2009.01.007 ↗
38. 10.1039/D4EN00962B10.1039/D4EN00962B ↗
39. 10.1155/2016/143183610.1155/2016/1431836 ↗
40. 10.1021/acsanm.8b0077910.1021/acsanm.8b00779 ↗
41. 10.1186/s12985-023-02194-w10.1186/s12985-023-02194-w ↗
42. 10.1155/2022/558908910.1155/2022/5589089 ↗
43. 10.1021/acsami.6b0661310.1021/acsami.6b06613 ↗
44. 10.1021/acsnano.0c0593710.1021/acsnano.0c05937 ↗
45. 10.1016/j.vetmic.2023.10970610.1016/j.vetmic.2023.109706 ↗
46. 10.1039/C6NR03878F10.1039/C6NR03878F ↗
47. 10.1016/j.immuni.2014.05.00710.1016/j.immuni.2014.05.007 ↗
48. 10.1016/j.neures.2015.09.00210.1016/j.neures.2015.09.002 ↗
49. 10.1073/pnas.060703810410.1073/pnas.0607038104 ↗
50. 10.1089/jir.2008.005010.1089/jir.2008.0050 ↗
51. 10.1016/j.jhep.2011.07.00910.1016/j.jhep.2011.07.009 ↗
52. 10.1016/j.virol.2008.10.02110.1016/j.virol.2008.10.021 ↗
53. 10.1128/JVI.00402-0710.1128/JVI.00402-07 ↗
54. 10.1016/j.bcp.2022.11502610.1016/j.bcp.2022.115026 ↗
55. 10.1073/pnas.160326911310.1073/pnas.1603269113 ↗
56. 10.4142/jvs.2021.22.e2010.4142/jvs.2021.22.e20 ↗
57. 10.1038/nnano.2007.26010.1038/nnano.2007.260 ↗
58. 10.1007/s43450-021-00182-110.1007/s43450-021-00182-1 ↗
59. 10.1021/acsnano.4c1567110.1021/acsnano.4c15671 ↗
60. 10.1590/0001-376520202020071810.1590/0001-3765202020200718 ↗
61. 10.1021/acsnano.0c0411710.1021/acsnano.0c04117 ↗